On April 23rd, 2025, the long-awaited results of the Phase III ASPEN trial of Brensocatib for the treatment of bronchiectasis were published in the New England Journal of Medicine.

The trial tested the efficacy of the the Dipeptidyl peptidase-1 inhibitor Brensocatib in a cohort of 1,680 adults and 41 adolescents and reports a significant reduction in exacerbations at both the 10mg and 25mg dose of Brensocatib compared to placebo, with the 25mg dose also bringing additional improvements in patient-reported quality of life and lung function. 

This positive trial represents a turning point in the natural history of bronchiectasis – underscoring bronchiectasis as an inflammatory disease that is treatable with anti-inflammatory therapy – and marks a new beginning for the those living with bronchiectasis.  

To read the full text, click here or the summary image below.